Avextra, established in 2019, is a German-based company emerging within the Manufacturing industry. The company is driven by a vision to harness the therapeutic potential of the cannabis plant to enhance patient quality of life.
Guided by its slogan — "The Essence of Cannabis-based Medicine is evidence" — Avextra aims to develop innovative, rigorously tested, and regulator-approved cannabis-based medicines. Their mission focuses on making these pharmaceutical solutions broadly accessible, thus addressing the needs of a wide patient demographic.
Despite being a young entity, Avextra has not specified recent funding rounds or investors, indicating potential opportunities for fresh capital infusion to advance its mission and expand market presence. The blend of scientific research, regulatory compliance, and patient-centric innovation positions Avextra as a compelling consideration for investors interested in the burgeoning cannabis-based therapeutic sector.